![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
20
Glaxosmithkline Research & Development Limited London Gb, based in United Kingdom, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their significant offerings is Clobetasone butyrate, Micronised, supported by a 'Valid' Certificate of Suitability (CEP) with the number R1-CEP 2002-248 - Rev 05
This Chemical Type CEP, issued on April 13, 2015, remains in force until January 01, 1970, ensuring its reliability within the pharmaceutical industry.
Substance Number 1090 associated with this CEP further emphasizes